AlphaRx, Cypress Bioscience deal

Cypress informed partner AlphaRx that it discontinued funding for development of Indaflex, a topical cream formulation of indomethacin. In 2007, Indaflex missed the primary endpoints in a Phase II trial to treat osteoarthritis (OA). AlphaRx said it will continue to develop Indaflex in China (see BioCentury, May 21, 2007 & April 17, 2006). ...